Calliditas Therapeutics AB (publ) Financials

Market Capitalization $1.05 Billion as of July 1, 2024

Valuations Metrics as of Jan. 25, 2025

Trailing PE	6.07
Forward PE
Price to Sales TTM	€0.43
Price to Book MRQ	€0.49
Enterprise to Revenue	1.07
Enterprise to EBITDA	6.20

Financial Reports as of Dec. 31, 2016

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2016-12-31
Profit Margin	7.00%
Operating Margin	11.43%
Return on Assets TTM	3.59%
Return on Equity TTM	9.88%

Income Statement

Revenue TTM	€1,976,126,976
Revenue per Share TTM	€16.45
Quarterly Revenue Growth	3.30%
Gross Profit TTM	€1,260,391,040
EBITDA	€308,723,000
Net Income to Common TTM	€138,360,992
Diluted EPS TTM	€1.15
Quarterly Earnings Growth YoY	10.60%

Balance Sheet

Total Cash MRQ	€433,728,000
Total Cash per Share MRQ	€3.61
Total Debt MRQ	€
Total Debt to Equity MRQ	13.18
Current Ratio MRQ	1.50
Book Value per Share MRQ	€14.14

Cash Flow

Operating Cash Flow TTM	€463,313,984
Levered Free Cash Flow TTM	€213,055,120

CALT Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	120,120,000
Float Shares	14,903,288
Avg 10 Volume	32,410
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	87.59%
% Held by Institutions	5.62%

Stock Price Summary

Beta	0.96
Fifty Two Week Low	€4.03
Fifty Two Week High	€7.16
Fifty Two Week Change	38.83%
Day 50 MA	€6.49
Day 200 MA	€5.86

Dividends and Splits

Forward Annual Dividend Rate	€1.00
Forward Annual Dividend Yield	14.33%
Trailing Annual Dividend Rate	€0.25
Trailing Annual Dividend Yield	3.58%
Payout Ratio	21.70%
Dividend Date
Ex Dividend Date	2024-05-20
Last Split Factor
Last Split Date	2001-06-18